)
UroGen Pharma (URGN) investor relations material
UroGen Pharma 3rd Annual Guggenheim Healthcare Innovation Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Commercial launch
ZUSDURI’s permanent J-code took effect in January; management views 2026 as its first full launch year and expects a steady, 4–5-year path to peak sales.
More than 95% of covered lives have access; over 650 physicians had tried ZUSDURI through September, against 6,500 core targets.
Unique prescribers rose from just over 450 through Q2 to over 650 in Q3; repeat writers increased from 45% through Q2 to 50% in Q3.
Early-adopter depth has driven revenue; management aims to broaden trial and convert physicians into repeat adopters. All physicians in an ATU who tried the drug said they would use it again.
Management maintained a $1bn-plus peak-sales opportunity; nearly all patients in practice complete all six instillations, and anecdotal responses in heavily pretreated patients mirror clinical results.
Market and competitive landscape
Management sees additional therapies as expanding the bladder-cancer market rather than creating a zero-sum contest; patients may cycle through treatments, and multiple entrants can encourage practice change.
ZUSDURI’s differentiation is a non-surgical six-week course; cited study results include an 80% complete response rate, 80% of responders still in response at one year, and median response duration unreached at 36 months.
U.S. low-grade bladder cancer prevalence is 400,000, with ~15% recurring in a given year; management said first-line use would take 10–20 years to reduce the recurrent-patient pool.
Pipeline and product lifecycle
UGN-103 offers easier mixing, several weeks of stability after reconstitution versus seven days for the current formulation, and lyophilization in three days versus about three weeks; expected benefits include supply flexibility and modest COGS improvement.
UGN-103 is advancing into a high-risk papillary study later this year; management sees an opportunity among ~20,000 papillary-only patients and plans to study the product across high-grade patient types.
UGN-103 patents include method-of-use protection through July 2044, composition-of-matter protection to mid-2035, and RTGel protection through 2041.
UGN-501 dosed its first patient in a Phase I study; its dual mechanism combines direct tumor lysis with an immune response, and gel delivery is intended to extend dwell time.
UGN-501 may also support development beyond bladder cancer, including intratumoral treatment in other specialty cancers.
- ZUSDURI drove Q3 revenue growth as UGN-103 advanced to FDA review.URGN
Q3 2026 - Strong demand for Zusduri and advancing pipeline programs signal robust growth prospects.URGN
H.C. Wainwright 28th Annual Global Investment Conference - Zusduri's strong launch and next-gen pipeline position the company for growth and innovation.URGN
12th Annual Cantor Fitzgerald Global Healthcare Conference - ZUSDURI's rapid adoption and robust pipeline position the company for sustained growth.URGN
Wells Fargo 21st Annual Healthcare Conference - First-in-class non-surgical therapies and strong pipeline drive innovation in urothelial cancer care.URGN
Corporate presentation - ZUSDURI revenue rose 73% QoQ as Q2 revenue reached $72.5 million and net loss narrowed.URGN
Q2 2026 - ZUSDURI's rapid uptake and strong clinical data position it for billion-dollar peak sales.URGN
Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - UGN-102 achieved 79.6% CR at 3 months and 82.3% 12-month durability in NMIBC, with low toxicity.URGN
Study Update - UGN-102 NDA accepted for June 2025 PDUFA; Jelmyto Q3 sales up, but full-year revenue to miss guidance.URGN
Q3 2024
)
)
)
)
)
)
)
)